Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A phase 1/2 trial of Daraxonrasib, Elironrasib, Zoldonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07397338 by Revolution Medicines, Inc., with 370 participants planned, started 2026-01-30 and due to reach its primary completion in 2029-05. Interventions recorded: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only). Conditions listed: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
- TrialStudy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu
Shares Zoldonrasib, Revolution Medicines, Cisplatin, Carboplatin.
- TrialStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Colorectal cancer.
- TrialStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
- TrialStudy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib.